Background: Eosinophils are prominent in some patients with asthma and are increased in the submucosa in a subgroup of obese patients with asthma (OAs). Surfactant protein A (SP-A) modulates host responses to infectious and environmental insults. Objective: We sought to determine whether SP-A levels are altered in OAs compared with a control group and to determine the implications of these alterations in SP-A levels in asthmatic patients. Methods: Bronchoalveolar lavage fluid from 23 lean, 12 overweight, and 20 obese subjects were examined for SP-A. Mouse tracheal epithelial cells grown at an air-liquid interface were used for mechanistic studies. SP-A 2/2 mice were challenged in allergen models, and exogenous SP-A therapy was given after the last challenge. Eosinophils were visualized and quantitated in lung parenchyma by means of immunostaining. Results: Significantly less SP-A (P 5 .002) was detected in samples from OAs compared with those from control subjects. A univariable regression model found SP-A levels were significantly negatively correlated with body mass index (r 5 20.33, P 5 .014), whereas multivariable modeling
Obesity is a major comorbidity associated with an increase in the incidence of asthma and is associated with poor asthma control and worsening asthma symptoms. 1 Asthma in obese patients is associated with phenotypic heterogeneity similar to that seen in lean patients with asthma (LAs), 2 and contrary to prior belief, a proportion of obese patients with asthma (OAs) demonstrate the presence of eosinophilic inflammation. 3, 4 The underlying mechanism that causes eosinophilia might differ in some OAs, in whom allergic sensitization might not be the primary cause of eosinophilia. 5 The initial studies aimed at characterizing eosinophilic inflammation in the lungs of OAs as opposed to those of LAs relied on sputum measurements. [6] [7] [8] [9] However, the reliability of sputum to accurately predict submucosal eosinophil counts in the airways of asthmatic patients was called into question after several key publications that demonstrated that in OAs high number of tissue eosinophils were identified in subjects with low levels of eosinophils in compartmental fluids. [10] [11] [12] [13] This discordance was demonstrated in patients with asthma of all severities. One mechanism to explain this persistence of tissue eosinophilia in obesity might be related to alterations in eosinophil trafficking; however, the underlying cause of these findings remains unclear.
Leptin and TNF-a levels are both increased in serum and bronchoalveolar lavage (BAL) fluid in obese patients relative to nonobese healthy control subjects, 3, 14, 15 and leptin has been associated with increases in BAL fluid TNF-a levels. 16 Leptin is known to mediate eosinophil chemotaxis and therefore might be a causal factor in the obesity-related changes in eosinophil [17] [18] [19] Furthermore, TNFa and leptin levels are associated with increased eosinophil activity, 17, 18, 20 which might worsen asthma control in patients with airway eosinophilia. In addition, studies in mice suggest that restoring normal body weight leads to reduction in TNF-a levels and improvement in lung inflammation and function in asthma models. 21 Surfactant protein A (SP-A) is a lung collectin that is thought to be an important mediator in regulating eosinophil activities and maintaining airway homeostasis. Previous studies have been controversial regarding altered SP-A levels in asthmatic patients, with some reporting an increase in SP-A levels 22 and others reporting a decrease in SP-A levels. 23, 24 Studies from our group and others have found that SP-A extracted from asthmatic patients is itself dysfunctional in regulating immune responses. 25, 26 The goal of our study was to determine whether SP-A levels are altered in OAs compared with healthy and overweight patients with and without asthma and to define mechanisms and potential consequences underlying this association.
METHODS

Study subjects
The Duke University Institutional Review Board approved the protocol. Subjects were recruited from the population in Durham County and the surrounding area. Informed consent was obtained from each subject (18-65 years of age). Lean subjects were defined as having a body mass index (BMI) of less than 25 kg/m 2 , whereas a BMI of between 25 kg/m 2 or greater and less than 30 kg/m 2 was considered overweight, and a BMI of 30 kg/m 2 or greater was considered obese. The BMI category for each subject was further categorized by the presence or absence of asthma. This stratification provided 6 groups including LAs, lean healthy subjects (LNs), overweight patients with asthma (OWAs), overweight healthy subjects, OAs, and obese healthy subjects. Asthmatic patients met the National Asthma Education and Prevention Program criteria for mild and moderate asthma. 27 The presence of atopy was determined by using skin prick testing. Healthy subjects had normal lung function and no history of atopy. Exclusion criteria included use of antibiotics or oral corticosteroids within 4 weeks of the study, a greater than a 10-pack-year history of smoking, and any other significant medical conditions. Research bronchoscopy with BAL was performed on subjects, as previously described. 25 See the Methods section in this article's Online Repository at www.jacionline.org for additional processing information.
Normal human SP-A extraction SP-A was purified from the BAL fluid of patients with alveolar proteinosis seen at Duke University Medical Center who were under institutional review board approval by using previously described methods. 28 Extracted SP-A had final endotoxin concentrations of less than 0.01 pg/mg SP-A.
BAL fluid analysis from obese mice
Obese mice (Lep ob/ob and Lepr db-9J
) were purchased from Jackson Laboratories (Bar Harbor, Me). All murine experiments were part of protocols approved by the Institutional Animal Care and Use Committee at Duke University, the University of Arizona, or the University of Vermont. For BAL, 0.1 mmol/L EDTA in PBS was used to flush the lungs with a volume of 1 mL to measure SP-A levels. The SP-A antibody used to detect mouse SP-A was purified in the laboratory of Dr Jo Rae Wright (Duke University) and used, as previously described. 29 
Mouse models of allergic airways disease
Wild-type (WT) and SP-A 2/2 mice were maintained on a C57BL/6J background (Jackson Laboratories). SP-A 2/2 mice were generated, as described previously. 30 See the Methods section in this article's Online Repository for methods of ovalbumin (OVA) and house dust mite (HDM) exposure models.
Histologic analysis of tissue eosinophilia
Left lung lobes were dissected and immersed in 10% buffered formalin for fixation. Embedded sections (4 mm) were mounted on Fisher-PLUS slides (Thermo Fisher Scientific, Waltham, Mass) and immunostained, as previously described, by using a well-characterized rabbit anti-mouse major basic protein (MBP) polyclonal antisera. 31 
Mouse tracheal epithelial cell cultures
Mouse tracheal cells were isolated from WT, SP-A 2/2 and TNF receptor
; Jackson Laboratories) mice and cultured, as previously described. 32 On the day of challenge, 50 mL of sterile media was added to the apical surface and flushed several times to remove the presecreted SP-A. Mouse tracheal epithelial cells (MTECs) were challenged with vehicle (media), TNF (100 ng/mL), or leptin (100 ng/mL) apically for either 24 hours or 5 days, after which the apical and basolateral secretions were collected for analysis of SP-A and eotaxin. Mouse eotaxin (eBioscience, San Diego, Calif) was assessed by means of ELISA, according to the manufacturer's instructions. A set of MTECs was assessed every other day with a voltmeter to determine epithelial integrity with the various challenges. Some MTECs were collected into TRI Reagent (Sigma, St Louis, Mo), and RNA was isolated by using standard methods. RT-PCR was performed with Bioline 2x SensiFAST SYBR no-ROX mix (Bioline Inc, Taunton, Mass) for expression levels of mouse SP-A using primers (see the Methods section in this article's Online Repository).
Statistical analysis
Please see the Methods section in this article's Online Repository for a detailed description of statistical analysis.
RESULTS
Demographics and baseline characteristics
Fifty-five subjects with analyzable BMI, asthma status, and SP-A levels were included in the study and were categorized as 11 OAs and 44 control subjects. The control group included 10 LAs, 13 LNs, 5 OWAs, 7 overweight healthy subjects, and 9 obese healthy subjects (Table I) . A significantly higher percentage of obese patients were female (P 5 .01). There was no significant difference in age between the groups (P 5 .495); however, obese subjects were slightly older (33.2 6 13.0 years) than control subjects (30.8 6 9.7 years). Significant imbalances were not found in race between the obese and control groups (P 5 .509); however, a higher percentage of the patients in the OA group (63.6%) were white compared with those in the control group (50.0%).
OAs demonstrated a significantly older age at asthma diagnosis (P 5 .046), with a higher percentage of OAs (55.6%) having a later onset asthma (> _12 years) compared with 8.3% in the LA and OWA groups combined. Baseline inhaled corticosteroid use was also trending higher in OAs (45.4%) compared with 7.1% in the LA and OWA groups (P 5 .056). No significant differences in the presence of allergic sensitization as characterized by skin prick tests were found between the OA (57.1%) and control (39.0%) groups (P 5 .433); however, LAs demonstrated a higher percentage of positive skin test results (83.3%) than OAs.
Lung function as related to BMI and asthma
The mean FEV 1 (percent predicted) was significantly different between groups (P 5 .013) and was higher in the control group (96.8% 6 12.5%) than in the OA group (85.2% 6 16.3%), as shown in Table II . The mean forced vital capacity (FVC [percent predicted]) was trending higher in the control group (103.3% 6 13.0%) than in the OA group (95.1% 6 18.1%) but was not statistically different (P 5 .089). The mean SP-A level was significantly lower (P 5 .002) in the OA group (0.4 6 0.6) than in the control group (1.5 6 1.0). No differences were observed in airway hyperresponsiveness, as determined based on methacholine PC 20 values between the control and OA groups (P 5 .839).
SP-A levels differ on the basis of obesity
Overall, statistically significant correlations were observed among the markers of inflammation and lung function (r 5 0.61 for FVC [percentage] and FEV 1 [percentage] and r 5 0.82 for IL-6 and TNF-a; see Table E1 in this article's Online Repository at www.jacionline.org). Pearson correlations were then determined among biomarkers within each weight category. We did not observe correlations between SP-A expression and other biomarkers overall or within each weight category. In contrast, patients with OA had the lowest SP-A levels, with significantly lower mean levels (0.4 6 0.6) in comparison with both the LAs (1.9 6 1.2, P 5 .002) and LNs (1.5 6 1. Table E1 ). Conversely, SP-A levels were modestly but positively correlated with FVC (percent predicted; r 5 0.21, P 5 .126) and FEV 1 (percent predicted; r 5 0.17, P 5 .203), demonstrating that increased SP-A levels can have some correlation with improved lung function; however, continuous BMI was the only statistically significant variable correlated with SP-A levels after considering all other biomarkers (TNF-a and IL-6), lung function measures (FVC [percentage] and FEV 1 [percentage]), and asthma status. If we treat BMI as a categorical variable (lean, overweight, and obese), then we find a significant negative correlation with SP-A levels and an interaction with asthma status that trends toward significance (P 5 .065).
Relationship between TNF-a and SP-A levels in pelleted BAL fluid cells TNF-a levels are increased in serum and BAL fluid in obese patients relative to levels in nonobese healthy control subjects. 15, 33 Because of the nature of our retrospective study, we were unable to measure TNF-a levels in cell-free lavage fluid or serum of our subjects. We analyzed TNF-a levels in a subset of our pelleted BAL samples in which SP-A levels were also measured. There was negative correlation, albeit nonsignificant, between SP-A and TNF-a levels overall and within the lean and overweight weight groups; however, the correlation was positive within the obese group (see Table E1 ). Hypothesizing an interaction with asthma, we considered the relationship in only asthmatic patients and found a negative correlation overall within each of the lean, overweight, and obese groups. Although our sample size was too small to make any definitive conclusions, the correlation between SP-A and TNF-a levels appeared stronger within the asthmatic patients if a subject was overweight or obese. 
BMI and asthma as predictors of lung function biomarkers
A univariable linear regression analysis found a statistically significant negative correlation between SP-A levels and continuous BMI (r 5 20.33, P 5 .014; Fig 1, B) . When adjusting for both BMI and asthma status in a multivariable model, both asthma (P 5 .017) and the interaction of asthma and BMI (P 5 .008) significantly predicted SP-A levels (see Table E2 in this article's Online Repository at www.jacionline.org). Similar results were found when predicting FVC (percentage) on the basis of BMI and asthma status. These results indicate that SP-A and FVC (percentage) values depend on asthma status (different intercepts for each group) and that the slope of the relationship is dependent on BMI if subjects have asthma, with obese subjects having lower values. However, only asthma (r 5 0.36, P 5.006) was predictive of FEV 1 (percentage). BMI and asthma group did not correlate with either TNF-a or IL-6 levels.
Obese mice demonstrate decreased SP-A levels in lavage fluid
To determine whether further mechanistic studies were possible in mouse models, we sought to determine whether differences in BAL SP-A levels exist in obese compared with lean mice of the same age and sex. We examined BAL SP-A levels from 2 common strains of obese mice: db/db (leptin receptor deficient) and ob/ob (leptin deficient). Both db/db and ob/ob mice weighed significantly more than lean mice at the time of BAL fluid harvest (Fig 2, B) . We determined that naive obese mice have significantly decreased levels of SP-A in cell-free BAL fluid compared with naive WT (lean) mice (Fig 2, A and C) .
TNF-a represses SP-A secretion from MTECs
Previous experiments in cell lines showed that TNF-a can reduce SP-A mRNA levels. [34] [35] [36] However, no studies in primary pulmonary cells have verified this finding or examined levels of SP-A secretion. We sought to determine whether TNF-a could also repress SP-A secretion from WT primary MTECs, which are known to secrete SP-A. 32 There were no significant differences in the levels of SP-A secreted in each individual transwell before challenge. Thereafter, the apical surface was challenged with either TNF-a, leptin, or vehicle (Fig 3, A) . Transepithelial resistance was assessed to verify that the epithelial tight junction integrity of the transwells remained the same throughout the challenges. There were no significant changes in transepithelial resistance in either vehicle-or TNF-challenged and leptin-challenged conditions for up to 5 days of challenge (Fig 3, B) . We detected a slight decrease in SP-A mRNA levels after treatment of MTECs with either TNF or leptin compared with vehicle only (Fig 3, C) . TNF-a treatment, but not leptin, resulted in a significant reduction in SP-A secretion into the apical supernatants at 24 hours (Fig 3, D) . Similar results were observed for up to 5 days of challenge (data not shown).
Because TNF-a is known to have pleiotropic functions that might not require specific receptor interactions, we sought to determine whether TNF-a repression of SP-A secretion was independent of TNF-R. MTECs were grown from WT and TNF-R 2/2 mice, and after 2 weeks at the air-liquid interface (ALI), they were challenged with TNF-a for 24 hours. Again, we demonstrated significant repression of SP-A in WT MTECs challenged with TNF-a versus vehicle; however, there was no appreciable decrease in SP-A secretion in TNF-a-challenged MTECs that lacked TNF-R (Fig 3, E) .
Exogenous SP-A therapy reduces tissue eosinophilia in allergic mouse models
In the human study we determined that OAs had significantly decreased SP-A levels, and prior publications have shown that OAs have significantly increased tissue eosinophilia regardless of asthma severity. Therefore we sought to determine whether SP-A might play a role in the resolution of eosinophilia in lung tissue. To determine the role of SP-A in eosinophil migration, we instilled exogenous human SP-A into the lungs of allergic SP-A 2/2 (nonobese) mice and examined tissue eosinophilia in the ''SP-A rescue'' mice compared with vehicle control mice. In the OVA (Fig 4, A) and HDM (Fig 4, E) models SP-A was given 1 day after the terminal challenge, a peak inflammatory time in both models. Lungs were examined for the presence of eosinophils 7 days after the last challenge. No BAL fluid or tissue eosinophilia was observed in unchallenged control mice (data not shown). In the OVA and HDM models significantly fewer BAL fluid eosinophils (Fig 4, C and G) and MBP 1 tissue eosinophils (Fig 4, B and F) were detected in the SP-A rescue group compared with the vehicle-treated groups.
SP-A-deficient MTECS have attenuated eotaxin secretion
MTECs from WT and SP-A 2/2 mice were grown at an ALI for 2 weeks, and baseline measurements of eotaxin production by naive epithelial cells were assessed. We found significantly less eotaxin secretion into the apical and basolateral compartments from SP-A 2/2 MTECs compared with WT MTECs (Fig 5, A) . We have shown that TNF-a is sufficient to decrease SP-A secretion from epithelial cells in culture (Fig 3, D) and that SP-A 2/2 MTECs secrete significantly less eotaxin at baseline compared with WT MTECs. Taken together, this suggests that TNF-a exposure would also result in decreased eotaxin secretion. Fig 5, B, shows a 30% reduction in basolateral eotaxin secretion from the TNF-a-treated WT MTECs compared with the nonstimulated control wells. There was no significant repression of eotaxin secretion in TNF-a-challenged MTECs that lacked TNF-R, suggesting this response is also receptor dependent. In support of these findings, we examined BAL fluid from OVA-treated WT and SP-A 2/2 mice and found that mice lacking SP-A have significantly less eotaxin in BAL fluid 7 days after the last challenge compared with WT mice (Fig 5, C) .
DISCUSSION
In the human studies presented here, we found that SP-A levels were negatively correlated with increased BMI. We demonstrated that OAs have significantly lower levels of BAL fluid SP-A compared with LAs and LNs. Mechanistically, we also found that a common cytokine upregulated in obesity, TNF-a, was sufficient to repress SP-A secretion and eotaxin production in a Fig 2, B) and have significantly lower SP-A levels in BAL fluid than lean mice (P < .01; Fig 2, C) . **P < .01 and ***P < .001, as compared with lean mice.
receptor-dependent manner. Using SP-A 2/2 mice and epithelial cell cultures grown at an ALI, our findings suggest a novel role for SP-A in promoting resolution of tissue eosinophilia by enhancing eotaxin production by epithelial cells. Taken together, we propose a model (Fig 6) in which increased TNF-a levels in obese subjects can result in attenuation of SP-A secretion. Although the loss of SP-A could affect many aspects of lung function and host defense, we propose that loss of functional SP-A is a contributing factor to the enhanced tissue eosinophilia that has been observed in several studies of OAs. 10, 13 Our studies in vitro support the notion that SP-A promotes movement of eosinophils from tissue indirectly by enhancing eotaxin production from airway epithelial cells. Additionally in the same MTEC culture wells in which TNF-a challenge attenuated SP-A secretion, we were able to verify that eotaxin secretion was also significantly decreased, both of which were dependent on the presence of the TNF-R. Taken together, these results support the concept that increased TNF-a levels can lead to decreased SP-A secretion, which results in decreased eotaxin production and impairment in eosinophil movement out of the tissue. In further support of our proposed model, we show that in 2 different mouse models of allergic airways disease, exogenously administered human ''SP-A therapy'' leads to significant reductions in tissue eosinophilia during the resolution phase compared with vehicle control therapy.
The epithelial lining fluid SP-A concentration has been reported to be as high as approximately 800 mg/mL, whereas that measured in lung lavage fluid was typically in the 30 mg/mL range. 37 A better understanding of SP-A levels in asthmatic patients has been an ongoing topic of research for more than a decade and has led to contradictory conclusions, likely based on heterogeneous characteristics of asthmatic subjects and sampling protocols. [22] [23] [24] Our studies propose the alternative novel concept that SP-A levels within asthmatic populations are significantly altered based on obesity and inversely correlated with BMI.
Several limitations of our study warrant consideration. First, all OAs recruited were female, and therefore no conclusions can be made with regard to male OAs. Second, there were differences in the use of inhaled corticosteroids by obese subjects and LAs. We do not believe that this had a major effect on SP-A levels because steroids have been shown to result in an increase in SP-A levels both in mouse models and premature infants. 38, 39 Third, high-speed pellets were obtained from BAL fluid that were then analyzed for SP-A, TNF, and IL-6 expression. This leads to the possibility that BAL fluid macrophages that can differentially bind SP-A in obese subjects and LAs could affect the amount of SP-A measured in our study. We observed lower SP-A levels in cell-free BAL fluid obtained from obese compared with lean mice, suggesting that macrophage populations are unnecessary to detect SP-A differences in the context of obesity.
We also acknowledge that the increased airway closure that occurs in OAs could affect sampling of these subjects and thus alter the readout of SP-A in BAL fluid. Although SP-A is predominantly produced by alveolar type II cells in the distal airway, SP-A is present in the central large airways and is produced by club cells and submucosal cells. Future studies should be conducted to determine whether increased compressive forces generated in the distal airways of obese subjects alter SP-A production.
Because of the retrospective study, we did not completely phenotype our patients using state-of-the-art biomarkers, which (Fig 3, C) but did cause a significant reduction in SP-A secretion into the apical supernatants (Fig 3, D) . **P < . A and E, Mice lacking SP-A were challenged in a standard OVA (Fig 4, A) or HDM (Fig 4, E) protocol. Twenty-four hours after the last challenge in either model, mice were given an SP-A rescue treatment (or vehicle), and lung tissue was harvested 6 days later for analysis of tissue eosinophilia by using anti-MBP staining. B, C, F, and G, In both the OVA (Fig 4, B and C) and HDM (Fig 4, F and G) models, SP-A rescue treatment led to significantly lower tissue and BAL fluid eosinophilia compared with vehicle treatment. *P < .05, **P < .01, and ***P < .001. D, Representative lung sections from OVA-treated mice that received vehicle (upper) or SP-A treatment. ae, Aerosol; in, intranasal; ip, intraperitoneal; V, vessel. mice demonstrated a significant reduction in eotaxin secretion in both the apical and basolateral supernatants compared with WT MTECs (n 5 3 independent experiments, 3-6 transwells per experiment). ***P < .001. B, WT and TNF-R 2/2 mice were challenged with TNF-a or vehicle for 24 hours, and eotaxin was assessed in the basolateral compartment (n 5 3-4 transwells per group). **P < .01. C, Eotaxin levels in BAL fluid from OVA-treated WT and SP-A 2/2 mice, as determined by means of ELISA (n 5 2 experimental sets combined and represented as fold relative to WT). *P < .05.
will be the approach taken in future studies to validate this observation. Likewise, we were unable to measure IL-6 and TNF levels in serum or cell-free BAL fluid or examine tissue eosinophilia in our obese subjects to compare with the previous reports.
We also acknowledge that our sample size was small, especially when creating 6 different subgroups based on BMI and asthma status. However, we had approximately 88% power to detect differences across means in a 1-way ANOVA design with 55 subjects, assuming a 0.05 significance level and a common SD within groups of 0.90.
Previous studies have reported decreased FVC in adult OAs compared with LAs 40 but no difference in FEV 1 . We observed decreased FEV 1 (percent predicted) in our OA cohort, which weakly correlated with SP-A levels. One study has suggested mechanical stress is sufficient to induce TNF-a production through Ca 21 release and receptor signaling. 41 This leads to the possibility that the increased compression inherently present in the lungs of OAs stimulates TNF-a production and thereby initiates the process that results in decreased SP-A levels and potential subsequent alterations in eosinophil trafficking. Future studies should determine whether increased compression of lung cells is sufficient to provoke TNF-a production and inhibit SP-A secretion. Our finding that TNF-a was unable to inhibit SP-A secretion when TNF-R was absent in epithelial cells suggests that this process is not a pleiotropic effect of TNF-a but rather a receptor-mediated pathway that should be further explored. Further studies are warranted to determine the effect of weight loss on SP-A secretion and tissue eosinophilia and, furthermore, whether targeted anti-TNF therapies might play a role in the management of OAs with refractory eosinophilic disease.
In conclusion, our study demonstrated a novel role for SP-A in modulating tissue eosinophilia in a manner that can be affected by obesity. This OA endotype is poorly understood, and the mechanisms that modulate tissue eosinophilia on the basis of obesity have not been well explained. We propose that obesity results in alterations in TNF-a levels because of either systemic inflammation or mechanical compression of the lung and that changes in TNF-a levels result in downstream decreases in SP-A levels and eotaxin secretion, with subsequent changes in eosinophil migration and lack of resolution of lung eosinophilia. 
METHODS
Bronchoscopy and BAL were performed, and SP-A, TNF-a, and IL-6 levels were quantified in our study subjects BAL fluid samples were centrifuged at 10,000 rpm for 20 minutes. The pelleted samples were examined by using Western blot analysis for the presence of SP-A (ab51891; Abcam, Cambridge, United Kingdom). SP-A levels per sample were determined by using densitometry for SP-A as a fraction of the total protein of each sample (determined by using bicinchoninic acid analysis). SP-A levels were also detected in a subset of pelleted BAL samples by using ELISA (catalog no. RD191139200R; BioVendor, Asheville, NC); in the same subset of pelleted BAL samples, TNF-a and IL-6 levels were quantitated by using multiplex Luminex analysis (Millipore, Temecula, Calif). 
OVA and HDM models
Histologic analysis of tissue eosinophilia with anti-MBP
In brief, antigen retrieval was carried out by incubating in 0.1% trypsin in PBS and 0.1% CaCl 2 (pH 7.8) for 30 minutes at 908C. After washing with 0.05% Tween 20 in PBS with 1% BSA (Sigma), lung sections were blocked with 10% normal goat serum in PBS (Vector Laboratories, Burlingame, Calif) and then incubated with a 1:500 dilution of rabbit anti-mouse MBP in 1% BSA overnight at 48C in a humid chamber.
RT-PCR primers
Primers were as follows: murine SP-A (forward: 59 GTA CAG TAG CCA  TGT CAC TAG G 39, reverse: 59 TGA AGC TCC TCA TCC AGG TAA G 39)  and cyclophilin (forward: 59 AGC ACT GGA GAG AAA GGA TTT GG 39,  reverse: 59 TCT TCT TGC TGG TCT TGC CAT T 39) .
Statistical analysis
Descriptive statistics were computed, including the mean and SD or median and range for continuous variables, as determined by data distribution, whereas counts and percentages were used to describe categorical variables with nonmissing values. Normality was assessed by using the Kolmogorov-Smirnov test and by reviewing normality plots. BMI was treated as both a continuous and categorical variable with 3 categories: lean (BMI < 25 kg/m 2 ), overweight (25 kg/m 2 < _ BMI < 30 kg/m 2 ), and obese (BMI > _ 30 kg/m 2 ). Six groups based on categorical BMI and asthma status were created, including LNs, LAs, overweight healthy subjects, OWAs, obese healthy subjects, and OAs. Pairwise comparison of interest was between OAs and all other BMI/asthma groups combined (control groups).
ANOVA (F-test) or the Kruskal-Wallis test was used to make comparisons between the OA and control groups for continuous variables based on the distribution, whereas the x 2 or Fisher exact test (expected cell counts < 5) was used for categorical variables. Pearson correlation coefficients with 95% CIs (based on Fisher Z transformation) were used to determine the relationship among SP-A levels, FEV 1 (percent predicted), FVC (percent predicted), TNF-a levels, and IL-6 levels overall and within each weight category. Linear regression models were used to determine both the univariable and multivariable correlation for each of SP-A level, FEV 1 (percent predicted), FVC (percent predicted), TNF-a level, and IL-6 level with continuous BMI, asthma status, and the interaction between BMI and asthma.
In murine experiments the Kruskal-Wallis and x 2 tests were used to make comparisons on the basis of obesity, experimental condition, or both. Linear regression was again used to determine the correlation between BMI and SP-A levels in murine BAL fluid. The t test was used to determine statistically significant differences in murine models.
Analyses were performed with SAS software (version 9.4) and SAS JMP software (SAS Institute, Cary, NC) and GraphPad Prism software (GraphPad Software, La Jolla, Calif). We did not adjust for multiple comparisons because all analyses were exploratory, and pairwise comparisons were avoided as much as possible by evaluating linear trends or differences across prespecified groups and by presenting CIs. Statistical significance was defined as a P value of .05 or less. 
